EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Geert R. D'Haens  1     Taku Kobayashi  2     Nathan Morris  3     Trevor Lissoos  3     Amy Hoover  3     Xingyuan Li  3     Vipin Arora  3     Catherine Milch  3     William Sandborn  4     Bruce E. Sands  5    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
2 Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
3 Eli Lilly and Company, Indianapolis, United States
4 University of California San Diego, La Jolla, United States
5 Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing